Home » Stocks » ABCM

Abcam PLC (ABCM)

Stock Price: $21.26 USD 0.51 (2.46%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 4.73B
Revenue (ttm) 329.11M
Net Income (ttm) 15.82M
Shares Out 226.72M
EPS (ttm) 0.08
PE Ratio 279.92
Forward PE 91.74
Dividend $0.15
Dividend Yield 0.71%
Trading Day May 7
Last Price $21.26
Previous Close $20.75
Change ($) 0.51
Change (%) 2.46%
Day's Open 20.80
Day's Range 20.70 - 21.32
Day's Volume 222,394
52-Week Range 17.88 - 24.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to...

1 month ago - Business Wire

Other stocks mentioned: ATHM, HSTM, JOBS, SAP
1 month ago - GuruFocus

CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Resea...

1 month ago - GlobeNewsWire

CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, to...

1 month ago - GlobeNewsWire

CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China...

2 months ago - GlobeNewsWire

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its ...

2 months ago - GlobeNewsWire

CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Hea...

2 months ago - GlobeNewsWire

Abingdon Health signs collaboration and co-marketing agreement with Abcam

2 months ago - GlobeNewsWire

CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appo...

3 months ago - GlobeNewsWire

Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well.

3 months ago - Seeking Alpha

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following release on 14 Se...

6 months ago - GlobeNewsWire

CAMBRIDGE, United Kingdom, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that, following consultation wit...

6 months ago - GlobeNewsWire

About ABCM

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex as... [Read more...]

Industry
Biotechnology
IPO Date
Oct 22, 2020
CEO
Murray Hennessy
Employees
1,600
Stock Exchange
NASDAQ
Ticker Symbol
ABCM
Full Company Profile

Financial Performance

In 2020, Abcam PLC's revenue was 260.00 million, an increase of 0.04% compared to the previous year's 259.90 million. Earnings were 12.50 million, a decrease of -72.22%.

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Abcam PLC stock is "Buy." The 12-month stock price forecast is 1,606.37, which is an increase of 7,455.83% from the latest price.

Price Target
$1,606.37
(7,455.83% upside)
Analyst Consensus: Buy